BUSINESS COMBINATIONS AND ACQUISITIONS (Details 2) (USD $) In Thousands, unless otherwise specified	0 Months Ended		0 Months Ended
Oct. 24, 2013 Optimer Pharmaceuticals, Inc.	Oct. 24, 2013 Optimer Pharmaceuticals, Inc.	Sep. 11, 2013 Trius Therapeutics, Inc.	Sep. 11, 2013 Trius Therapeutics, Inc.
Total Acquisition-Date Fair Value
Cash transferred	$ 569,452		$ 695,710
Contingent consideration		115,634		4,603
Total consideration transferred	$ 685,086		$ 700,313

Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 30

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 30

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

Name:	us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration